{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:57:01Z","timestamp":1761663421383,"version":"build-2065373602"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["VR 2012-3440","VR-Link 2013-6710"],"award-info":[{"award-number":["VR 2012-3440","VR-Link 2013-6710"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI45008"],"award-info":[{"award-number":["P30 AI45008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.meegid.2015.11.014","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T13:01:20Z","timestamp":1447851680000},"page":"192-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments"],"prefix":"10.1016","volume":"37","author":[{"given":"Gianluca","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo Maria","family":"Paganotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Soeria-Atmadja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Ramogola-Masire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Vullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Lennart","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2015.11.014_bb0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5501\/wjv.v4.i3.198","article-title":"Pharmacogenetics as a tool to tailor antiretroviral therapy: a review","volume":"4","author":"Aceti","year":"2015","journal-title":"World J. Virol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0010","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","article-title":"Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug\u2013drug interaction with zidovudine","volume":"37","author":"B\u00e9langer","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.meegid.2015.11.014_bb0015","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3851\/IMP2320","article-title":"Determinants of HIV drug resistance and public health implications in low- and middle-income countries","volume":"17","author":"Bertagnolio","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0020","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/FPC.0b013e32835a5af2","article-title":"Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians","volume":"22","author":"Bertrand","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jit466","article-title":"Efavirenz and rifampicin-isoniazid based anti-tuberculosis treatment drug\u2013drug interaction is dependent on CYP2B6 and NAT2 genetic polymorphisms: ANRS12154 study in Cambodia","volume":"209","author":"Bertrand","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0030","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1128\/AAC.02379-13","article-title":"Pharmacokinetics of rifampin and isoniazid in tuberculosis\u2013HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment","volume":"58","author":"Bhatt","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"Bonnet","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.106.102525","article-title":"Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms","volume":"318","author":"Bumpus","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0045","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/jac\/dks207","article-title":"Significant pharmacokinetic interactions between artemether\/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults","volume":"67","author":"Byakika-Kibwika","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0050","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1128\/AAC.01537-08","article-title":"Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients","volume":"53","author":"Cabrera","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2125.2012.04163.x","article-title":"Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices","volume":"74","author":"Calcagno","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0060","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/infdis\/jit111","article-title":"Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings","volume":"207","author":"Cambiano","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.9.081307.164258","article-title":"African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping","volume":"9","author":"Campbell","year":"2008","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"7","key":"10.1016\/j.meegid.2015.11.014_bb0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400mg daily versus 600mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"Carey","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0075","doi-asserted-by":"crossref","first-page":"137192","DOI":"10.1155\/2012\/137192","article-title":"Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (plan B), and efavirenz","volume":"2012","author":"Carten","year":"2012","journal-title":"Infect. Dis. Obstet. Gynecol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0080","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1128\/AAC.00486-13","article-title":"Induction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells","volume":"57","author":"Chan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-BM3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FTD.0b013e3181ea953c","article-title":"CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients","volume":"32","author":"Chen","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.meegid.2015.11.014_bb0095","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1128\/AAC.02508-12","article-title":"HIV-positive Nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection","volume":"57","author":"Chijioke-Nwauche","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/dmd.104.001107","article-title":"Haplotype structure and allele frequencies of CYP2B6 in a Korean population","volume":"32","author":"Cho","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.meegid.2015.11.014_bb0105","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1128\/AAC.00883-10","article-title":"Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz","volume":"55","author":"Cho","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0110","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00512-10","article-title":"Population pharmacokinetic\u2013pharmacogenetic study of nevirapine in HIV-infected Cambodian patients","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0115","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis","volume":"61","author":"Cohen","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa","volume":"14","author":"Cohen","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.clpt.6100040","article-title":"Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions","volume":"81","author":"Cohn","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bcp.2009.03.029","article-title":"Human hepatic CYP2B6 developmental expression: the impact of age and genotype","volume":"78","author":"Croom","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0140","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/AAC.02532-14","article-title":"Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6","volume":"58","author":"Court","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-015-0004-2","article-title":"CYP2B6*6, CYP2B6*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe","volume":"16","author":"Dhoro","year":"2015","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0165","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1128\/AAC.02069-13","article-title":"Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi","volume":"58","author":"Dickinson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0170","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0175","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","article-title":"Understanding the pharmacokinetics of coartem","volume":"12","author":"Djimd\u00e9","year":"2009","journal-title":"Malar. J."},{"key":"10.1016\/j.meegid.2015.11.014_bb0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiu429","article-title":"Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection","volume":"211","author":"Dooley","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0185","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.10.94","article-title":"Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients","volume":"11","author":"Elens","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0190","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.meegid.2015.11.014_bb0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/1872312811206040004","article-title":"The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes","volume":"6","author":"Ericsson","year":"2012","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.meegid.2015.11.014_bb0200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2015.11.014_bb0205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":"Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers","volume":"320","author":"Faucette","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0210","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0b013e3283593602","article-title":"Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine","volume":"26","author":"Frasco","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0215","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/522175","article-title":"Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26","volume":"45","author":"Gatanaga","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-6405-7-32","article-title":"Presence of the CYP2B6 516G>T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients","volume":"7","author":"Gounden","year":"2010","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0230","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/QAI.0000000000000268","article-title":"Outcomes of antiretroviral therapy over a 10-year period of expansion: a multicohort analysis of African and Asian HIV programs","volume":"67","author":"Grimsrud","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0235","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/QAI.0b013e31817c1ed0","article-title":"Slow efavirenz metabolism genotype is common in Botswana","volume":"49","author":"Gross","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0240","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s11095-006-9083-5","article-title":"Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese","volume":"23","author":"Guan","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.meegid.2015.11.014_bb0245","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0250","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an adult AIDS clinical trials group study","volume":"192","author":"Haas","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0255","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/jac\/dku110","article-title":"Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes","volume":"69","author":"Haas","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0260","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/jac\/dku088","article-title":"Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti","volume":"69","author":"Haas","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0265","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/jac\/dkr304","article-title":"Long-term effect of efavirenz autoinduction on plasma\/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients","volume":"66","author":"Habtewold","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0270","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/tpj.2012.46","article-title":"Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients","volume":"13","author":"Habtewold","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.meegid.2015.11.014_bb0275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0280","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-002-0499-5","article-title":"Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population","volume":"58","author":"Hiratsuka","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0285","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0290","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bcp.12529","article-title":"Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications","volume":"79","author":"Hoglund","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0295","doi-asserted-by":"crossref","first-page":"18448","DOI":"10.7448\/IAS.16.1.18448","article-title":"Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya","volume":"16","author":"Hubacher","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.meegid.2015.11.014_bb0300","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1479-7364-5-4-265","article-title":"Analysis of pharmacogenetic traits in two distinct South African populations","volume":"5","author":"Ikediobi","year":"2011","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0305","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1093\/jac\/dkq369","article-title":"Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection","volume":"65","author":"Jamshidi","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0310","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/cid\/ciu286","article-title":"Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children","volume":"59","author":"Kakuru","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0315","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40262-013-0110-5","article-title":"Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals","volume":"53","author":"Kiang","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.meegid.2015.11.014_bb0320","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz","volume":"15","author":"Klein","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0325","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1128\/AAC.05265-11","article-title":"Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients","volume":"55","author":"Kredo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0330","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0335","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","article-title":"Paradoxically elevated efavirenz concentrations in HIV\/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy","volume":"25","author":"Kwara","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0340","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0345","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/QAI.0000000000000134","article-title":"Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women","volume":"66","author":"Landolt","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0350","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0355","article-title":"Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2015.11.014_bb0360","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/FPC.0b013e32834a522e","article-title":"Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine","volume":"21","author":"Lehr","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0365","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.meegid.2015.11.014_bb0370","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/pgs.11.160","article-title":"Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV\/AIDS treatment","volume":"13","author":"Li","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0375","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiq043","article-title":"Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study","volume":"203","author":"Lubomirov","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0380","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/cid\/civ155","article-title":"Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study","volume":"60","author":"Luetkemeyer","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1124\/dmd.31.4.421","article-title":"Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes","volume":"31","author":"Madan","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.meegid.2015.11.014_bb0390","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1475-2875-13-205","article-title":"Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy","volume":"13","author":"Maganda","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.meegid.2015.11.014_bb0395","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12936-015-0695-2","article-title":"The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment","volume":"14","author":"Maganda","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.meegid.2015.11.014_bb0400","article-title":"CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV\u2013malaria-coinfected patients","author":"Maganda","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.meegid.2015.11.014_bb0405","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1468-1293.2008.00689.x","article-title":"Cytochrome P450 2B6 516G_T is associated with plasma concentrations of nevirapine at both 200mg twice daily and 400mg once daily in an ethnically diverse population","volume":"10","author":"Mahungu","year":"2009","journal-title":"HIV Med."},{"key":"10.1016\/j.meegid.2015.11.014_bb0410","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-011-1118-0","article-title":"CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans","volume":"68","author":"Maimbo","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0415","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 non-nucleoside reverse transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0420","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.02023-12","article-title":"Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV\/tuberculosis-coinfected patients","volume":"57","author":"Manosuthi","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0425","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijantimicag.2013.10.022","article-title":"CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy","volume":"43","author":"Manosuthi","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.meegid.2015.11.014_bb0430","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0435","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-005-0092-9","article-title":"Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea","volume":"62","author":"Mehlotra","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0440","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2007.02884.x","article-title":"CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV\/AIDS treatment","volume":"64","author":"Mehlotra","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","article-title":"Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans","volume":"72","author":"Mouly","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0450","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans","volume":"68","author":"Mukonzo","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0455","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-13-261","article-title":"Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study","volume":"13","author":"Mukonzo","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0460","doi-asserted-by":"crossref","first-page":"e86919","DOI":"10.1371\/journal.pone.0086919","article-title":"Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes","volume":"9","author":"Mukonzo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2015.11.014_bb0465","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/QAI.0b013e3182569f57","article-title":"Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms","volume":"60","author":"Mutwa","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0470","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/QAD.0000000000000050","article-title":"Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness","volume":"27","author":"Nanda","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0475","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/clpt.2011.129","article-title":"Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis","volume":"90","author":"Ngaimisi","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0480","doi-asserted-by":"crossref","first-page":"e67946","DOI":"10.1371\/journal.pone.0067946","article-title":"Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two Sub-Saharan Africa populations","volume":"8","author":"Ngaimisi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2015.11.014_bb1000","series-title":"Panel on antiretroviral guidelines for adults and adolescents","article-title":"Department of Health and Human Services","author":"NIH","year":"2014"},{"key":"10.1016\/j.meegid.2015.11.014_bb0485","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.FP0040296","article-title":"Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities","volume":"96","author":"Nishimura","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.meegid.2015.11.014_bb0490","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1128\/AAC.05130-11","article-title":"In vitro activity of antiretroviral drugs against Plasmodium falciparum","volume":"55","author":"Nsanzabana","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0495","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G>T (*6) variant and effect on the population pharmacokinetics of efavirenza in HIV\/AIDS outpatients in Zimbabwe","volume":"64","author":"Nyakutira","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0500","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.meegid.2015.08.003","article-title":"CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon","volume":"35","author":"Paganotti","year":"2015","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0505","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/jhg.2009.20","article-title":"A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups","volume":"54","author":"Parathyras","year":"2009","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.meegid.2015.11.014_bb0510","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1468-1293.2007.00432.x","article-title":"Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda","volume":"8","author":"Penzak","year":"2007","journal-title":"HIV Med."},{"key":"10.1016\/j.meegid.2015.11.014_bb0515","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/QAD.0000000000000177","article-title":"Implementing the jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies","volume":"28","author":"Perry","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0520","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0525","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","article-title":"CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in south India","volume":"53","author":"Ramachandran","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0530","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0535","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0540","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Rodriguez-Novoa","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.meegid.2015.11.014_bb0545","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0010-7824(99)00109-2","article-title":"Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations","volume":"60","author":"Rosenberg","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.meegid.2015.11.014_bb0550","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"Rosenbloom","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.meegid.2015.11.014_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0560","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0565","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism","volume":"45","author":"Saitoh","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0570","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0575","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jac\/dkt372","article-title":"Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients","volume":"69","author":"Sarfo","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"S3","key":"10.1016\/j.meegid.2015.11.014_bb0580","doi-asserted-by":"crossref","first-page":"19484","DOI":"10.7448\/IAS.17.4.19484","article-title":"Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant","volume":"17","author":"Scarsi","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.meegid.2015.11.014_bb0585","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkr087","article-title":"Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals","volume":"66","author":"Schipani","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3851\/IMP1725","article-title":"The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women","volume":"16","author":"Sevinsky","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0595","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1023\/A:1016430825740","article-title":"Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture","volume":"19","author":"Stormer","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.meegid.2015.11.014_bb0600","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/QAI.0b013e31822b8bf8","article-title":"Combined oral contraceptives and antiretroviral PK\/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi","volume":"58","author":"Stuart","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0605","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1365-2125.2012.04288.x","article-title":"Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults","volume":"74","author":"Sukasem","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0610","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2133\/dmpk.DMPK-12-RG-120","article-title":"High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections","volume":"28","author":"Sukasem","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.meegid.2015.11.014_bb0615","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2133\/dmpk.DMPK-13-RG-077","volume":"29","author":"Sukasem","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.meegid.2015.11.014_bb0620","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s15010-013-0560-6","article-title":"Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism","volume":"42","author":"Sukasem","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.meegid.2015.11.014_bb0625","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2012.00236","article-title":"ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV\/AIDS patients","volume":"3","author":"Swart","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.meegid.2015.11.014_bb0630","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1875692111201010043","article-title":"CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two Bantu-speaking populations from Cameroon and South Africa: implications for global pharmacogenetics","volume":"10","author":"Swart","year":"2012","journal-title":"Curr. Pharmacogenomics Pers. Med."},{"key":"10.1016\/j.meegid.2015.11.014_bb0635","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","article-title":"High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV\/AIDS patients","volume":"23","author":"Swart","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0640","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.meegid.2015.11.014_bb0645","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/135965350801300601","article-title":"A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations","volume":"13","author":"ter Heine","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2015.11.014_bb0650","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17425255.2013.772579","article-title":"Drug interactions between antiretrovirals and hormonal contraceptives","volume":"9","author":"Tseng","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0655","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"author":"United Nations (UN), Department of Economic and Social Affairs, Population Division","key":"10.1016\/j.meegid.2015.11.014_bb0660"},{"key":"10.1016\/j.meegid.2015.11.014_bb0665","series-title":"Sustaining Human Progress: Reducing Vulnerabilities and Building Resilience","article-title":"Human development report 2014","author":"UNDP (United Nations Development Programme)","year":"2014"},{"key":"10.1016\/j.meegid.2015.11.014_bb0670","series-title":"UNAIDS Report on the Global AIDS Epidemic 2013","article-title":"Global Report","author":"UNAIDS","year":"2013"},{"key":"10.1016\/j.meegid.2015.11.014_bb0675","first-page":"78","article-title":"Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV\/TB co-infected Thai adults under anti-retroviral therapy","volume":"43","author":"Uttayamakul","year":"2012","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"10.1016\/j.meegid.2015.11.014_bb0680","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/infdis\/jit223","article-title":"Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission","volume":"208","author":"Vardhanabhuti","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2015.11.014_bb0685","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-008-0573-8","article-title":"Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam","volume":"65","author":"Veiga","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0690","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.meegid.2015.11.014_bb0695","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0700","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.meegid.2015.11.014_bb0705","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.10.002","article-title":"Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093","volume":"77","author":"Watts","year":"2008","journal-title":"Contraception"},{"author":"WHO (World Health Organization)","key":"10.1016\/j.meegid.2015.11.014_bb0710"},{"author":"WHO (World Health Organization)","key":"10.1016\/j.meegid.2015.11.014_bb0715"},{"author":"WHO (World Health Organization)","key":"10.1016\/j.meegid.2015.11.014_bb0720"},{"key":"10.1016\/j.meegid.2015.11.014_bb0725","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/TCRM.S2143","article-title":"Evaluation of extended and continuous use oral contraceptives","volume":"4","author":"Wright","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.meegid.2015.11.014_bb0730","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.meegid.2015.11.014_bb0735","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3748\/wjg.v13.i14.2100","article-title":"Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations","volume":"13","author":"Xu","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.meegid.2015.11.014_bb0740","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: a prospective cohort study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.meegid.2015.11.014_bb0745","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.meegid.2015.11.014_bb0750","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.meegid.2015.11.014_bb0755","doi-asserted-by":"crossref","first-page":"e55197","DOI":"10.1371\/journal.pone.0055197","article-title":"ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2015.11.014_bb0760","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1124\/mol.104.008086","article-title":"A natural CYP2B6 TATA box polymorphism (\u221282T>C) leading to enhanced transcription and relocation of the transcriptional start site","volume":"67","author":"Zukunft","year":"2005","journal-title":"Mol. Pharmacol."}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134815300435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134815300435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:31:47Z","timestamp":1761575507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134815300435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":152,"alternative-id":["S1567134815300435"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2015.11.014","relation":{},"ISSN":["1567-1348"],"issn-type":[{"type":"print","value":"1567-1348"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2015.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}